

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
RLL-475US

In Re Application Of: **SINGH et al.**

| Application No. | Filing Date  | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|--------------|----------|--------------|----------------|------------------|
| 10/596,013      | May 25, 2006 | TBA      | 26815        | TBA            | TBA              |

Title: **PHARMACEUTICAL COMPOSITIONS COMPRISING NATEGLINIDE AND A SURFACTANT**

Address to:  
**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-475US

In Re Application of: SINGH et al.

| Application No. | Filing Date  | Examiner | Customer No. | Group Art Unit | Confirmation No. |
|-----------------|--------------|----------|--------------|----------------|------------------|
| 10/596,013      | May 25, 2006 | TBA      | 26815        | TBA            | TBA              |

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING NATEGLINIDE AND A SURFACTANT

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

|  |
|--|
| I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa |
| <br><br>(Date)   |
| <br><br>Signature  |
| <br><br>Typed or Printed Name of Person Signing Certificate  |


\*This certificate may only be used if paying by deposit account.

  
Signature

William D. Hare, Esq.  
Reg. No. 44,739

Customer No. 26,815

**Certificate of Mailing by First Class Mail**

|  |
|--|
| I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as <del>first class</del> <sup>Express</sup> mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on |
| <br>January 23, 2007   |
| <br>(Date)   |
| <br><br>Signature of Person Mailing Correspondence   |
| <br>Michelle Morgan  |
| <br>Typed or Printed Name of Person Mailing Certificate  |

Dated: January 23, 2007

CC:

|  |                                 |                        |
|--|---------------------------------|------------------------|
| <b>INFORMATION DISCLOSURE CITATION</b> | Docket No.: RLL-475US           | Serial No.: 10/596,013 |
|  | Applicants: SINGH <i>et al.</i> |                        |
|  | Filed: 5/25/2006                | Group:                 |

| U.S. PATENT DOCUMENTS |    |                 |           |                      |       |          |                               |
|-----------------------|----|-----------------|-----------|----------------------|-------|----------|-------------------------------|
| EXAMINER<br>INITIAL   |    | DOCUMENT NUMBER | DATE      | NAME                 | CLASS | SUBCLASS | FILING DATE<br>IF APPROPRIATE |
|                       | A1 | 6,559,188       | 5/6/2003  | Gatlin <i>et al.</i> | 514   | 641      |                               |
|                       | A2 | 2003/0021843    | 1/30/2003 | Makino <i>et al.</i> | 424   | 468      |                               |
|                       | A3 | 2004/002544     | 1/1/2004  | Makino <i>et al.</i> | 514   | 563      |                               |
|                       |    |                 |           |                      |       |          |                               |
|                       |    |                 |           |                      |       |          |                               |
|                       |    |                 |           |                      |       |          |                               |
|                       |    |                 |           |                      |       |          |                               |

| FOREIGN PATENT DOCUMENTS |    |                 |            |         |       |          |                         |
|--------------------------|----|-----------------|------------|---------|-------|----------|-------------------------|
|                          |    | DOCUMENT NUMBER | DATE       | COUNTRY | CLASS | SUBCLASS | TRANSLATION<br>YES   NO |
|                          | B1 | EP 0 128 249    | 12/19/1984 | EPO     | C07K  | 5/06     |                         |
|                          | B2 | EP 0 196 222    | 10/1/1986  | EPO     | C07C  | 233/81   |                         |
|                          | B3 | EP 0 526 171    | 2/3/1993   | EPO     | C07C  | 233/63   |                         |
|                          | B4 | EP 1 334 720    | 8/13/2003  | EPO     | A61K  | 31/198   |                         |
|                          | B5 | EP 1 334 721    | 8/13/2003  | EPO     | A61K  | 31/198   |                         |
|                          | B6 | WO 2005/020979  | 3/10/2005  | PCT     | A61K  | 31/198   |                         |
|                          |    |                 |            |         |       |          |                         |
|                          |    |                 |            |         |       |          |                         |
|                          |    |                 |            |         |       |          |                         |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) |    |   |
|--|----|---|
|  | C1 | JP Stanley, "The Theory and Practice of Industrial Pharmacy", 2nd Edition, pgs. 108-109, Lackman et al. (eds), Lea & Febiger (pub), Philadelphia, PA (1976) |
|  |    |   |
|  |    |   |

|  |                 |
|--|-----------------|
| EXAMINER   | DATE CONSIDERED |
| <p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> |                 |